Provide a clear, concise title that accurately reflects the main topic, finding, innovation, or educational value of the submission. Remember, characters in your title are included in the size limit.

Author information does not count towards the character limit.

The Submitting Author is automatically listed as first and presenting author. You may change this after adding authors. Submitting authors should ensure that any co-authors included are aware they are being listed on the abstract.

The Presenting Author will serve as the primary contact for the abstract and will receive all communication, including notification of acceptance or rejection on 4 December. It is their responsibility to inform all co-authors of the submission’s outcome. If the abstract is accepted, the presenter will receive a presentation invitation on 18 December and will have until 22 January 2027 to confirm or withdraw the abstract, or change the presenter to another co-author if needed. The presenter (if not also the submitter) will be required to disclose any financial relationships with ACCME-defined ineligible companies. The presenter is required to register for and attend the Annual Meeting in person. Registration fees are not waived for presenters.

Co-Authors included should be those who contribute significantly to the intellectual content of the abstract (maximum 50 authors). You can use the ISHLT database search tool on the submission site to find and add your authors. Authors will be listed in the author block in the order they are added but can be rearranged after adding.

Late-Breaking Submission Categories are organized into four Core Therapies to help guide your category selection:

• HEART (Advanced Heart Failure & Transplantation)
• LUNG (Advanced Lung Failure & Transplantation)
• MCS (Mechanical Circulatory Support)
• PVD (Pulmonary Vascular Disease (PAH & CTEPH)

You may submit your abstract only once. Submitting the same abstract multiple times, or splitting one study into multiple submissions, is not allowed. If submissions are found to be too similar or duplicated, they may be rejected.

You will be asked to select the Primary Practice Area most relevant to your abstract even if it is different from your own primary area of practice, and additional relevant practice areas, from the following list:

• Anesthesiology & Critical Care
• Cardiology
• Cardiothoracic Surgery
• Infectious Diseases
• Nursing & Allied Health
• Pathology
• Pediatrics
• Pharmacy
• Pulmonology
• Research & Immunology

To ensure transparency and maintain the integrity of our scientific program in accordance with ACCME accreditation standards, several questions will be asked regarding funding sources and affiliations. This information allows us to implement appropriate mitigation strategies, meet reporting requirements, and accurately acknowledge the support behind the research—whether from industry, ISHLT, or ISHLT-managed registries.

• Is the presenting author an employee or owner of a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients? (Yes/No). If yes, identify the company.
• Is this abstract being funded (in part or in whole) by a industry? (Yes/No). If yes, identify the company.

In this step, the body of the late-breaking abstract (Purpose, Methods, and Endpoints) and any tables or images are entered. Follow the links on the site to enter each element.

A $25 (USD) processing fee must accompany each abstract. ISHLT accepts payment only in the form of MasterCard, Visa and American Express. Purchase orders, checks, and electronic bank transfers will not be accepted. This fee is non-refundable and used to cover the cost of submission and processing.

Once you've finished all steps, this page will indicate the submission is COMPLETE and no further action is required. However, we strongly encourage you to review your Submission carefully, including the list of authors and all content, to ensure everything is accurate. You can make corrections to any portion, including authors, by the deadline of Tuesday, 29 September 2026 at 11:59 PM ET / Wednesday, 30 September at 3:59 UTC..